Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction

Summary

The contribution of coagulation factors and fibrinolytic variables to the development of ischaemic arterial disease is still not clearly established. The PRIME study is a prospective cohort study of myocardial infarction in men aged 50-59 years and recruited from three MONICA field centers in France (Lille, Strasbourg and Toulouse) and the center in Northern Ireland (Belfast). Baseline examination included measurement of plasma fibrinogen, factor VII, and PAI-1 activity in over 10,500 participants. We investigated the associations of these haemo-static variables with cardiovascular risk factors, prevalent atherosclerotic disease and geographical area. Fibrinogen level increased with age, smoking, waist-to-hip ratio, LDL-cholesterol, and it decreased with educational level, leisure physical activity, alcohol intake and HDL-cholesterol. Factor VII activity increased with body mass index, waist-to-hip ratio, triglycerides, HDL- and LDL-cholesterol. PAI-1 activity increased with body mass index, waist-to-hip ratio, triglycerides, alcohol intake, smoking, and decreased with leisure physical activity. PAI-1 level was higher in diabetic subjects than in subjects without diabetes. Cardiovascular risk factors explained 8%, 9%, and 26% of the total variance in fibrinogen, factor VII, and PAI-1, respectively. Compared with participants without prevalent cardiovascular disease, those with previous myocardial infarction (n = 280), angina pectoris (n = 230), or peripheral vascular disease (n = 19) had significantly higher levels of fibrinogen, but those with stroke (n = 67) had not. PAI-1 activity showed a similar pattern of association. The odds ratio for cardiovascular disease associated with a rise of a one standard deviation in fibrinogen and PAI-1 was 1.31 (95% confidence interval: 1.20 to 1.42, p <0.001) and 1.38 (95% confidence interval: 1.27 to 1.49, p <0.001), respectively. After adjustment for cardiovascular risk factors, these associations were attenuated but remained highly significant. There was no significant association between factor VII activity and prevalent cardiovascular disease. Fibrinogen level and, to a lesser extent, factor VII and PAI-1 activity were higher in Northern Ireland than France after adjustment for the main cardiovascular risk factors. These geographical variations are consistent with the 2 to 3-fold higher incidence of myocardial infarction in Northern Ireland than France. Our results provide further epidemiological evidence for a possible role of fibrinogen and PAI-1 in the pathogenesis of coronary heart disease.

• References

• 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 210-8 242-50.
• 2 Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-36.
• 3 Scarabin PY. Haemostatic variables and arterial thrombotic disease: epidemiological evidence. In: Hypercoagulable states: fundamental aspets, acquired disorders, and congenital thrombophilia. Eds: Seghatchian MJ, Samama MM, Hecker SP. CRC Press; 1996: 209-16.
• 4 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North RR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
• 5 Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-44.
• 6 Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
• 7 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-6.
• 8 Junker R, Heinrich J, Schulte H, van de Loo J, Assman G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscl Thromb Vasc Biol 1997; 17: 1539-44.
• 9 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 1102-8.
• 10 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. Arterioscler Thromb 1992; 12: 1063-70.
• 11 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-55.
• 12 Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 337: 850-1.
• 13 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
• 14 Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
• 15 Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
• 16 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
• 17 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
• 18 Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993; 88: 2030-4.
• 19 Ridker PM, Vaughan DE, Stampfer MJ, Manson JR, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
• 20 Ridker PM, Hennekens CH, Stampfer MJ, Manson JR, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
• 21 Smith FB, Lee AJ, Fowkes FRG, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
• 22 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscler Thromb 1993; 13: 1412-7.
• 23 Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-61.
• 24 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
• 25 Brozovic M, Stirling Y, Harricks C, North WRS, Meade TW. Factor VII in an industrial population. Brit J Haematol 1974; 28: 381-91.
• 26 Friedewald W, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultra-centrifuge. Clin Chem 1972; 18: 920-4.
• 27 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
• 28 Fowkes FGR, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
• 29 Folsom AR, Wu KK, Shahar E, Davis CE. Association of haemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscl Thromb 1993; 13: 1829-36.
• 30 Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama M, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. Arterioscl Thromb 1993; 13: 886-91.
• 31 Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the cardiovascular health study. Arterioscl Thromb Vasc Biol 199 15: 1269-79.
• 32 Sharp DS, Abbott RD, Burchfiel CM, Rodriguez BL, Tracy RP, Yano K, Curb JD. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. Arterioscl Thromb Vasc Biol 1996; 16: 262-8.
• 33 Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-3.
• 34 The WHO MONICA Project.. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994; 90: 583-612.
• 35 Iso H, Folsom AR, Sato S, Wu KK, Shimamoto T, Koike K, Iida M, Komachi Y. Plasma fibrinogen and its correlates in Japonese and US population samples. Arterioscler Thromb 1993; 13: 783-90.
• 36 Balleisen L, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemio-logical study on factor VII, factor VIII and fibrinogen in an industrial population-I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost 1985; 54: 475-9.
• 37 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-9.
• 38 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 39 Green F, Hamsten A, Blombäck M, Humphries S. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-20.
• 40 Behague I, Poirier O, Nicaud V, Evans AE, Arveiler D, Luc G, Cambou JP, Scarabin PY, Bara L, Green F, Cambien F. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction – The ECTIM Study. Circulation 1996; 93: 440-9.
• 41 Davey-Smith G, Shipley MJ, Rose G. Magnitude and causes of socioeconomic differentials in mortality: evidence from the Whitehall Study. J Epidemiol Community Health 1990; 44: 265-70.
• 42 Lang T, Ducimetière P, Arveiler D, Amouyel P, Cambou JP, Ruidavets JB, Montaye M, Meyer V, Bingham A. Occupational categories and cardiovascular risk factors: distinct relationships with incidence and case fatality from acute coronary heart disease. Results from the French WHO-MONICA project, 1985-89, in men aged 30-59. Int J Epidemiol 1997; 26: 47-57.
• 43 Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O’Brien J. Childhood social circumstances and psychosocial and behavorial factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008-13.
• 44 Elwood PC, Yarnell JW, Pickering J, Fehily AM, O’Brien JR. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J 1993; 69: 183-7.
• 45 Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sexe. Results from the second MONICA Augsburg survey, 1989 to 1990. Arterioscler Thromb 1992; 12: 780-8.
• 46 Eliasson M, Evrin PE. Lundblad. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513-24.
• 47 Moor M, Silveira A, van’t Hoogt F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vas Biol 1995; 15: 655-64.
• 48 Lane S, Green FR, Scarabin PY, Nicaud V, Bara L, Humphries SE, Evans AE, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and controls in Belfast and in France but is not a strong indicator of MI risk in the ECTIM Study. Atherosclerosis 1996; 119: 119-27.
• 49 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
• 50 Saha N, Heng CK, Mozoomdar BP, Reuben EM, Soh HT, Low PS, Tay JSH, Liu Y, Hong S. Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease. Atherosclerosis 1995; 117: 33-42.
• 51 Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VII : baseline data on the relation to blood pressure, blood glucose, uric acid and lipid fractions. Thromb Haemost 1985; 54: 721-3.
• 52 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for an increased conversion of VII to a-VIIa in hyperlipidemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-58.
• 53 Scarabin PY, Bara L, Samama M, Orssaud G. Further evidence that activated factor VII is related to plasma lipids. Brit J Haematol 1985; 61: 186-7.
• 54 Carvalho de Sousa J, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoprotein. J Clin Pathol 1988; 41: 940-4.
• 55 Hoffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1992; 12: 267-270.
• 56 Scarabin PY, Vissac AM, Kirzin JM, Bourgeat P, Amiral J, Agher R, Guize L. Population correlates of coagulation factor VII: importance of age, gender, and menopausal status as determinants of activated factor VII. Arterioscl Thromb Vasc Biol 1996; 16: 1170-76.
• 57 Iacovello L, Di Castelnuovo A, De Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
• 58 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans AE, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM Study. Thromb Haemos 1995; 74: 928-32.
• 59 Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42: 719-23.
• 60 Scarabin PY, Bonithon-Kopp C, Bara L, Guize L, Samama M. Relationship between plasminogen activator inhibitor activity and menopausal status. Fibrinolysis 1990; 4: 233-6.
• 61 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
• 62 ECAT Angina Pectoris Study Group.. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
• 63 Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the haemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-73.
• 64 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
• 65 Meade TW, Chakbabarti R, Haines AP, North WRS, and Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-6.
• 66 Allen RA, Kluft C, Brommer EJP. Effect of chonic smoking on fibrinolysis. Arteriosclerosis 1985; 5: 443-50.
• 67 Hendriks HF, Veenstra J, Velthuis-te Wierik EJ, Schaafsma G, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J 1994; 308: 1003-6.
• 68 Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 1994; 272: 929-33.
• 69 Lee AJ, Flanagan PA, Rumley A, Fowkes FGR, Lowe GDO. Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population. Fibrinolysis 1995; 8: 49-54.
• 70 Shaukat N, Douglas JT, Bennet JL, de Bono DP. Can physical activity explain the differences in insulin levels and fibrinolytic activity between young Indo-origin and European relatives of patients with coronary artery disease?. Fibrinolysis 1995; 9: 55-63.